Table A2.
Duration of ADT by Treatment Arm and Protocol Risk Group
| Protocol Risk Group* | Duration of Initial ADT (months) |
|||||
|---|---|---|---|---|---|---|
| No. of Patients | Minimum | Q1 | Median | Q3 | Maximum | |
| CIMRT | ||||||
| Intermediate | 20 | 1.0 | 2.2 | 3.7 | 4.1 | 24.0 |
| High | 51 | 7.0 | 23.8 | 24.1 | 25.1 | 34.3 |
| HIMRT | ||||||
| Intermediate | 15 | 0.6 | 3.1 | 4.0 | 5.5 | 24.0 |
| High | 53 | 3.0 | 14.1 | 24.0 | 25.1 | 72.9 |
Abbreviations: ADT, androgen deprivation therapy; CIMRT, conventional fractionated intensity-modulated radiotherapy; HIMRT, hypofractionated intensity-modulated radiotherapy; Q1, first quartile; Q3, third quartile.
*
Intent for those classified as intermediate risk per protocol definition, and who began ADT before protocol entry, was administration of short-term ADT ≤ 4 months duration (three patients received ADT > 6.5 months). Intent for those classified as high risk per protocol definition was administration of long-term ADT of 2 years duration (two patients received ADT < 6.5 months; one received ADT > 35 months).